DIA428.38+4.41 1.04%
SPX6,000.36+61.06 1.03%
IXIC19,529.95+231.50 1.20%

China's Tian Ruixiang Bets Big On Health Insurance AI With Ucare Acquisition

Benzinga·05/30/2025 12:51:00
Listen to the news

TIAN RUIXIANG Holdings Ltd. (NASDAQ:TIRX), a China-based insurance broker, announced on Friday it is acquiring Ucare Inc. in an all-share deal worth $150 million, aiming to enhance its role in China's fast-growing health insurance sector.

Ucare runs the country's only cloud-based, AI-powered hospital and insurance risk management platform. Under the agreement, TIRX's subsidiary VitaCare Limited will issue more than 101 million Class A shares to Ucare's shareholders. The transaction is expected to close by July 2025.

Ucare's AI platform leverages a vast hospital database to help providers and insurers cut fraud, reduce administrative costs, and improve clinical accuracy. The company serves over 4,000 hospitals and has reportedly saved nearly $7 billion in healthcare costs as of late 2024. In its last fiscal year, Ucare reported $5.4 million in revenue and $0.6 million in profit.

Also Read: Regeneron, Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data

CEO Wei Zhu said the partnership would support further integration of generative AI into clinical pathways and insurance tools. TIRX Chairwoman Sheng Xu said Ucare's data and platform would help TIRX diversify revenue and strengthen product design.

Once finalized, Ucare will operate as a wholly owned unit of VitaCare. Part of the share release is tied to Ucare meeting a revenue target of 150 million Chinese Yuan (around $20.82 million) within three years.

The acquisition aligns with ongoing reforms in China's health insurance system and reflects a broader industry trend toward AI-driven solutions that merge insurance and care delivery.

Related ETFs: Global X Telemedicine & Digital Health ETF (NASDAQ:EDOC), iShares MSCI China ETF (NASDAQ:MCHI).

Price Action: TIRX shares are trading higher by 38.8% to $2.54 premarket at last check Friday.

Read Next:

Photo via Shutterstock

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.